Determinants of Blood Pressure Response to Quinapril in Black and White Hypertensive Patients
Open Access
- 1 June 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 43 (6) , 1202-1207
- https://doi.org/10.1161/01.hyp.0000127924.67353.86
Abstract
Race has been considered an important factor in determining blood pressure response to treatment and selection of antihypertensive drug therapy. Data collected during a clinical trial that evaluated rapidity of medication up-titration with blood pressure response to monotherapy with the angiotensin-converting enzyme (ACE) inhibitor quinapril were used to characterize response in 533 black and 2046 white participants. Our objectives were to examine the influence of race and other factors on blood pressure response and to assess the degree to which nonrace factors account for apparent racial differences in response. Average systolic and diastolic blood pressure responses (baseline minus follow-up) to treatment were assessed with treatment groups combined. Crude systolic and diastolic blood pressure responses averaged 4.7 and 2.4 mm Hg less, respectively, in black compared with white participants; however, the response distributions largely overlapped. In multivariate linear regression models adjusted for study design variables and measured participant characteristics, the racial difference in systolic response was reduced by 51% to 2.3 mm Hg, and diastolic response by 21% to 1.9 mm Hg. In these models, participant characteristics, including age, gender, body size, and pretreatment blood pressure severity, significantly predicted either attenuated or enhanced blood pressure response to treatment. Our findings demonstrate that a large source of variability of blood pressure response to treatment is within, not between, racial groups, and that factors that vary at the level of the individual contribute to apparent racial differences in response to treatment.Keywords
This publication has 25 references indexed in Scilit:
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertensionKidney International, 2002
- Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertensionClinical Therapeutics, 2001
- Effect of race on hypertension and antihypertensive therapyInt. Journal of Clinical Pharmacology and Therapeutics, 2000
- Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ DamageCurrent Medical Research and Opinion, 2000
- Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trialsAmerican Heart Journal, 1999
- The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureArchives of internal medicine (1960), 1997
- Hypertension in Africa and Effectiveness of Its Management with Various Classes of Antihypertensive Drugs and in Different Socio-Economic and Cultural EnvironmentsClinical and Experimental Hypertension, 1993
- Hypertension in BlacksPrimary Care: Clinics in Office Practice, 1991
- A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive BlacksArchives of internal medicine (1960), 1990